Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: A systematic review and indirect comparison meta-analysis

Psychopharmacology

Volumn 197, Issue 1, 2008, Pages 1-11

  Peterson, Kim ^a   McDonagh, Marian S ^a   Fu, Rongwei ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adult ADHD; Atomoxetine; Bupropion; Meta analysis; Psychopharmacology; Stimulant; Systematic review

Indexed keywords

ADDERALL XL; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE; MODAFINIL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EMBASE; HUMAN; HYPERTENSION; LANGUAGE; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL; REVIEW; SLEEP DISORDER; SYSTEMATIC REVIEW; TACHYCARDIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DOPAMINE UPTAKE INHIBITORS; HUMANS; PROPYLAMINES; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 40949127505     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0996-4     Document Type: Review

References (44)

1. Anonymous (2001) Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews CRD Report Number 4 (2nd edition). York, UK, NHS Centre for Reviews and Dissemination
2. Asherson P (2005) Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother 5:525-539
3. Barkley RA (2004) Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27:233-260
4. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T et al (2006) A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 59:829-835
5. Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR (2005) Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 21:195-206
6. Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF (2005) A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 100:1868-1874
7. Chou R, Fu R, Huffman LH, Korthuis PT (2006) Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses [see comment]. Lancet 368:1503-1515
8. Dodson WW (2005) Pharmacotherapy of adult ADHD. J Clin Psychol 61:589-606
9. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test [see comment]. BMJ 315:629-634
10. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31:140-149
11. Food and Drug Administration (2006a) Drug Safety and Risk Management Advisory Committee Meeting, vol 2006
12. Food and Drug Administration (2006b) Pediatric Advisory Committee, vol 2006
13. Food and Drug Administration Drugs@FDA, http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/
14. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D (2001) Current methods of the third U.S. Preventive Services Task Force. Am J Prev Med 20:21-35
15. Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P et al (2005) The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 47:565-572
16. Kessler RC, Adler L, Barkley RA, Biederman J, Conners CK, Demler O et al (2006) The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry 163:716-723
17. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK (2004) Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 34:973-982
18. Levin ED, Conners CK, Silva D, Canu W, March J (2001) Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 9:83-90
19. Levin F, Evans S, Brooks D, Kalbag A, Garawi F, Nunes E (2006) Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 81:137-148
20. Levin FR, Evans SM, Brooks DJ, Garawi F (2007) Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87:20-29
21. Matza LS, Paramore C, Prasad M (2005) A review of the economic burden of ADHD. Cost Eff Resour Alloc 3:5
22. McDonagh MS, Peterson K (2006) Drug class review of pharmacologic treatment of ADHD, vol 2006
23. McGough JJ, Smalley SL, McCracken JT, Yang M, Del'Homme M, Lynn DE, Loo S (2005) Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 162:1621-1627
24. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ et al (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120
25. Montano B (2004) Diagnosis and treatment of ADHD in adults in primary care. J Clin Psychiatry 65(Suppl 3):18-21
26. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z (1999) A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder [comment]. Aust N Z J Psychiatry 33:494-502
27. Reimherr FW, Hedges DW, Strong RE, Marchant BK, Williams ED (2005) Bupropion SR in adults with ADHD: A short-term, placebo-controlled trial. Neuropsychiatric Disease and Treatment 1:245-251
28. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK (2007) A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93-101
29. Riccio CA, Wolfe M, Davis B, Romine C, George C, Lee D (2005) Attention deficit hyperactivity disorder: manifestation in adulthood. Arch Clin Neuropsychol 20:249-269
30. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N et al (2002) Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 10:286-294
31. Secnik K, Swensen A, Lage MJ (2005) Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics 23:93-102
32. Song F, Altman DG, Glenny A-M, Deeks JJ (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 326:472
33. Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434-443
34. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J et al (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695
35. Spencer T, Biederman J, Wilens T, Faraone S, Prince J, Gerard K et al (2001) Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder [comment]. Arch Gen Psychiatry 58:775-782
36. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J et al (2005) A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456-463
37. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L, Adult ARG (2007) Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 61:1380-1387
38. Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux P-Y, Secnik K (2004) Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health 35:346.e341-349
39. Terrin NSCH, Lau J (2005) In an empirical evaluation of funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 58:894-901
40. Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK et al (2006) Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 11:625-639
41. Weiss M, Hechtman L, The Adult ARG (2006) A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 67:611-619
42. Wender PH, Reimherr FW, Wood D, Ward M (1985) A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 142:547-552
43. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J et al (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158:282-288
44. Wilens TE, Haight BR, Horrigan JP et al (2005) Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 57:793-801